Sign in
Stories
Eisai Invests in Alzheimer's Blood Test
Share
Alpha Cognition's Business Update
Alzheimer's Innovations: A Clinical Adva...
Alzheimer's Market Growth Projections
AlzeCure's Drug Therapy Focus
Breakthrough Alzheimer's Blood Test Stud...
Breakthrough Alzheimer's Detection Test
Overview
API
Japanese drugmaker Eisai to invest $15 million in U.S. biotech firm C2N Diagnostics, focusing on Alzheimer's blood test utilizing amyloid beta detection.
Ask a question
How might the partnership between Eisai and C2N impact the future of Alzheimer's diagnosis?
In what ways could this investment influence the broader landscape of Alzheimer's research and treatment?
What challenges and opportunities could arise from using blood tests for Alzheimer's detection?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage